Browse by Audience
Chronic pain is a complex condition that remains resistant to current therapeutics. We previously synthesized a series of -acyl amino acids (NAAAs) that inhibit the glycine transporter, GlyT2, some of […]
Learn More >Spinal cord injury (SCI) causes neural disconnection and persistent neurological deficits, so axon sprouting and plasticity might promote recovery. Soluble Nogo-Receptor-Fc decoy (AXER-204) blocks inhibitors of axon growth and promotes […]
Learn More >Previous studies have demonstrated the role of γ-aminobutyric acid type B (GABA) receptors in skin-related conditions and pain. However, most studies have focused on the main effects of GABA on […]
Learn More >Drug addiction is a devastating condition that poses a serious burden on the society. The use of some drugs like morphine for their tremendous analgesic properties is also accompanied with […]
Learn More >There is a major societal need for analgesics with less tolerance, dependence, and abuse liability. Preclinical rodent studies suggest that bifunctional ligands with both mu (MOPr) and delta (DOPr) opioid […]
Learn More >There is no effective treatment for peripheral nerve injury-induced chronic neuropathic pain (NP), which profoundly impacts the quality of life of those affected. Transmembraneprotein100 (TMEM100) is considered to be a […]
Learn More >Tricyclic antidepressants (TCAs), such as desipramine (DMI), are effective at managing neuropathic pain symptoms but often take several weeks to become effective and also lead to considerable side effects. Tianeptine […]
Learn More >The outcome of migraine patients retreated with monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (anti-CGRP) or its receptor (anti-CGRPr) is not completely known.
Learn More >Real-time glucose monitoring conventionally involves non-bioresorbable semi-implantable glucose sensors, causing infection and pain during removal. Despite bioresorbable electronics serves as excellent alternatives, the bioresorbable sensor dissolves in aqueous environments with […]
Learn More >We have previously shown that intradermal injection of high-molecular-weight hyaluronan (500-1200 kDa) produces localized antihyperalgesia in preclinical models of inflammatory and neuropathic pain. In the present experiments, we studied the […]
Learn More >